title: [Effect of 12-Months Therapy With Perindopril A on Structural-Functional State of the Microcirculatory Vascular Bed in Patients With Chronic Heart Failure].
abstract: Experimental and clinical data confirm that endothelial dysfunction (ED) of microvessels is one of mechanisms of progression of chronic heart failure (CHF).
  
  
  
  To assess the impact of 12-month treatment with perindopril A (5-10 mg/day) on structural and functional state of microcirculatory vascular bed in patients with CHF.
  
  
  
  We included into this study 30 patients aged 45-70 years with NYHA class II-III CHF. All patients received perindopril A 5-10 mg/day for 12 months. For assessment of endothelial function we used test with reactive hyperemia. During this test we evaluated flow dependent vasodilation by photoplethysmography, and registered the state of skin capillary network by computer videocapillaroscopy. We also measured level of proinflammatory cytokines - von Willebrand factor, and -tumor necrosis factor (-TNF).
  
  
  
  After treatment with perindopril A 5 we observed improvement of microvascular endothelial function (occlusion index rose from 1.5 [1.2; 2.9] to 2.0 [1.7; 2.4], p=0.03), and of functional state of the finger skin capillary network (percentage of perfused capillaries rose from 88 [77; 95] to 95 [87; 97], p=0.05, percentage of recovered capillaries rose from 8 [4.5; 12.1] to 14.2 [9.3; 17.1], p=0.04). These effects were associated with significant lowering of (-TNF) level (from 6.58 [3.72, 10.3] to 3.35 [0.15; 6.33] g/L, p<0.01).
authors.affiliation: Sechenovs First Moscow State Medical University, Moscow, Russia.
authors.forename: Yu N
authors.initials: YN
authors.lastname: Belenkov
authors.affiliation: Sechenovs First Moscow State Medical University, Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Privalova
authors.affiliation: Sechenovs First Moscow State Medical University, Moscow, Russia.
authors.forename: Yu A
authors.initials: YA
authors.lastname: Danilogorodskaya
authors.affiliation: Sechenovs First Moscow State Medical University, Moscow, Russia.
authors.forename: E A
authors.initials: EA
authors.lastname: Zheleznykh
authors.affiliation: Sechenovs First Moscow State Medical University, Moscow, Russia.
authors.forename: A A
authors.initials: AA
authors.lastname: Shchendrygina
authors.affiliation: Sechenovs First Moscow State Medical University, Moscow, Russia.
authors.forename: M I
authors.initials: MI
authors.lastname: Tishman
authors.affiliation: Sechenovs First Moscow State Medical University, Moscow, Russia.
authors.forename: I S
authors.initials: IS
authors.lastname: Chekneva
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D008875:Middle Aged; D020913:Perindopril / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril